Lipid-lowering effectiveness of a Russian generic of atorvastatin in patients with various hyperlipidaemia phenotypes
Abstract
Aim. To assess lipid-lowering effectiveness of generic atorvastatin in patients with various hyperlipidaemia (HLP) phenotypes in an open, short-term (four weeks) study.
Material and methods. All participants were divided into two groups — with isolated hypercholesterolemia (HCH) and normal fasting triglycerides, (n=25), and with combined HLP and TG levels >1,7 mmol/l (n=26). Atorvastain dose was 20 mg/d. Serum levels of total cholesterol (TCH), TG and high-density lipoprotein cholesterol (HDL- CH) were measured by standard enzyme methods. Medication effectiveness was assessed by the reduction in low- density lipoprotein CH (LDL-CH) and TG levels.
Results. In both groups, the medication significantly decreased serum levels of LDL-CH by 34-36,4%, without any substantial inter-group difference. However, lipid-lowering effect in patients with lower baseline TG levels was stronger than in individuals with normal TG concentrations — 27,1% and 12,9%, respectively (p=0,027).
Conclusion. Cholesterol-lowering effect of generic atorvastatin (20 mg/d) was similar in patients with IIa and IIb HL. The effect on TG levels depended on HLP phenotype and was greater in individuals with higher baseline TG levels.
About the Authors
P. P. Malyshev
L.A. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex
Russian Federation
Russian Federation
Moscow
T. A. Rozhkova
L.A. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex
Russian Federation
Russian Federation
Moscow
Z. Yu. Malmakova
L.A. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex
Russian Federation
Russian Federation
Moscow
V. V. Kukharchuk
L.A. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex
Russian Federation
Russian Federation
Moscow
References
1. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B-12.
2. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998;19(Suppl M): M8-14.
3. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a metaanalysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-9.
4. Brown WV. Is hypertriglyceridemia a risk factor in patients with nor¬mal cholesterol levels? ACC Cardiosource Rev J 2006; 15: 88-91.
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
6. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, III пересмотр. Приложение 3 к журналу “Кардиоваск тер профил” 2007; 6.
7. Малышев П.П., Каминная В.И., Рожкова Т.А. и др. Сравнительная гиполипидемическая эффективность препаратов аторвастатина Атомакс® и Липримар у пациентов с гиперхолестеринемией. Эффек фармакотер кардиол ангиол 2007; 3: 2-6.
8. Ginsberg HN. Effects of statins on triglyceride metabolism. Am J Cardiol 1998; 81: 32B-5.
9. Schoonjans K, Peinado-Onsurbe J, Fruchart JC, et al. HMGCoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C—III and LPL. FEBS Lett 1999; 452: 160-4.
10. Schaefer EJ, McNamara JR, Tayler T, et al. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart dis¬ease patients versus control subjects. Am J Cardiol 2002; 90: 689-96.
11. Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six- week tolerability of simvastatin 80 and 160 mg per day. Am J Cardiol 1997; 79: 38-42.
12. Stein EA, Lane M, Laskarzewski P. Comparisons of statins in hyper¬triglyceridemia. Am J Cardiol 1998; 81: 66B-9.
13. Caslake MJ, Stewart G, Day SP, et al. Phenotypic-dependent and-independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 2003; 171: 245-53.
14. Karalis DG, Ishisaka DY, Luo D, et al. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia. Am J Cardiol 2007; 100: 445-9.
15. Havel RJ. Triglyceride-rich lipoproteins and atherosclerosis: new perspectives. Am J Clin Nutr 1994; 59: 795-9.
16. Sakabe K, Fukuda N, Wakayama K, et al. Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholester¬olemia. Am J Cardiol 2004; 94: 497-500.
Review
For citations:
Malyshev P.P., Rozhkova T.A., Malmakova Z.Yu., Kukharchuk V.V. Lipid-lowering effectiveness of a Russian generic of atorvastatin in patients with various hyperlipidaemia phenotypes. Cardiovascular Therapy and Prevention. 2009;8(6):16-20. (In Russ.)
Views:
412
Email this article 
